<DOC>
	<DOCNO>NCT02071862</DOCNO>
	<brief_summary>Many tumor cell , contrast normal cell , show require amino acid glutamine produce energy growth survival . To exploit dependence tumor glutamine , CB-839 , potent selective inhibitor first enzyme glutamine utilization , glutaminase , test Phase 1 study patient solid tumor . This study open-label Phase 1 evaluation CB-839 patient advance solid tumor . The study conduct 2 part . Part 1 dose escalation study enrol patient locally-advanced , metastatic and/or refractory solid tumor receive CB-839 capsule orally twice three time daily . In Part 2 , patient follow disease enrol : A ) Triple-Negative Breast Cancer , B ) Non-Small Cell Lung Cancer ( adenocarcinoma ) , C ) Renal Cell Cancer , D ) Mesothelioma , E ) Fumarate hydratase ( FH ) -deficient tumor , F ) Succinate dehydrogenase ( SDH ) -deficient gastrointestinal stromal tumor ( GIST ) , G ) SDH-deficient non-GIST tumor , H ) tumor harbor mutation isocitrate dehydrogenase-1 ( IDH1 ) IDH2 , I ) cMyc mutation tumor . As extension Parts 1 &amp; 2 , patient treat CB-839 combination standard chemotherapy . Combination group include : Pac-CB , CBE , CB-Erl , CBD , CB-Cabo . Pac-CB : patient locally-advanced metastatic TNBC treat paclitaxel CB-839 . CBE : patient advance clear cell RCC papillary RCC treat everolimus combination CB-839 . CB-Erl : patient advance NSCLC lack T790M EGFR mutation treat erlotinib CB-839 . CBD : patient NSCLC harbor KRAS mutation treat docetaxel CB-839 . CB-Cabo : patient histologically confirm diagnosis locally-advanced , inoperable metastatic RCC treat cabozantinib combination CB-839 . All patient assess safety , pharmacokinetics ( plasma concentration drug ) , pharmacodynamics ( inhibition glutaminase ) , biomarkers ( biochemical marker may predict responsiveness later study ) , tumor response .</brief_summary>
	<brief_title>Study Glutaminase Inhibitor CB-839 Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion Advanced malignancy relapse and/or refractory available therapy confer clinical benefit . Newly diagnose patient refuse standard treatment regimen also eligible Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Life Expectancy least 3 month Adequate hepatic , renal , cardiac , hematologic function Measurable disease RECIST criterion Ability provide write informed consent accordance federal , local , institutional guideline Exclusion Criteria Any current previous malignancy Chemotherapy , radiation therapy , hormonal therapy , immunotherapy biological therapy , investigational agent within 21 day Unable receive medication oral medication Major surgery within 28 day Cycle 1 Day 1 Active infection require within 2 week prior first dose study drug Patients HIV , Hepatitis A , B C CMV reactivation Significant neurotoxicity/neuropathy ( Grade 3 high ) within 14 day first dose study drug Conditions could interfere treatment protocolrelated procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tumor metabolism</keyword>
	<keyword>Glutaminase</keyword>
	<keyword>Glutamine</keyword>
	<keyword>Tricarboxylic acid ( TCA ) cycle</keyword>
</DOC>